has received approval of an Abbreviated New Drug Application (ANDA) from the Food and Drug Administration (FDA) for Prochlorperazine Edisylate Injection.
Gensia Sicor's version of prochlorperazine edisylate injection will be available in two presentations: a 5mg/mL 2mL vial and a 5mg/mL 10mL vial.